200 related articles for article (PubMed ID: 9060082)
1. Invasive, high grade transitional cell carcinoma of the bladder treated with transurethral resection. A survival analysis focusing on TUR as monotherapy.
Roosen JU; Geertsen U; Jahn H; Weinreich J; Nissen HM
Scand J Urol Nephrol; 1997 Feb; 31(1):39-42. PubMed ID: 9060082
[TBL] [Abstract][Full Text] [Related]
2. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
[TBL] [Abstract][Full Text] [Related]
3. Management of high-risk non-muscle invasive bladder cancer.
Brausi M; Olaru V
Minerva Urol Nefrol; 2012 Dec; 64(4):255-60. PubMed ID: 23288212
[TBL] [Abstract][Full Text] [Related]
4. Retrospective analysis of transurethral resection, second-look resection, and long-term chemo-metaphylaxis for superficial bladder cancer: indications and efficacy of a differentiated approach.
Schulze M; Stotz N; Rassweiler J
J Endourol; 2007 Dec; 21(12):1533-41. PubMed ID: 18186695
[TBL] [Abstract][Full Text] [Related]
5. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
[TBL] [Abstract][Full Text] [Related]
6. [Results of radical cystectomy for management of invasive bladder cancer with special reference to prognostic factors and quality of life depending on the type of urinary diversion].
Słojewski M
Ann Acad Med Stetin; 2000; 46():217-29. PubMed ID: 11712306
[TBL] [Abstract][Full Text] [Related]
7. Value of repeat radical transurethral resection for selected patients with muscle-invasive bladder cancer.
Li Z; Li Y; Lu Q; Chen J
ANZ J Surg; 2018 Oct; 88(10):1033-1036. PubMed ID: 29974604
[TBL] [Abstract][Full Text] [Related]
8. The role of surveillance in the treatment of patients with muscle-invasive bladder cancer after chemotherapy.
Hellenthal NJ; Ramirez ML; Evans CP; Devere White RW
BJU Int; 2010 Feb; 105(4):485-8. PubMed ID: 19849694
[TBL] [Abstract][Full Text] [Related]
9. Treatment options for high-risk T1 bladder cancer: status quo and future perspectives of radiochemotherapy.
Weiss C; Ott OJ; Wittlinger M; Krause SF; Fietkau R; Sauer R; Rödel C
Strahlenther Onkol; 2008 Sep; 184(9):443-9. PubMed ID: 19016022
[TBL] [Abstract][Full Text] [Related]
10. The best management of superficial bladder tumours: comparing TUR alone versus TUR combined with intravesical chemotherapy modalities?
Altay B; Girgin C; Kefi A; Cikili N
Int Urol Nephrol; 2000; 32(1):53-8. PubMed ID: 11057773
[TBL] [Abstract][Full Text] [Related]
11. Clinical study of G3 superficial bladder cancer without concomitant CIS treated with conservative therapy.
Saika T; Tsushima T; Nasu Y; Arata R; Kaku H; Kusaka N; Kumon H
Jpn J Clin Oncol; 2002 Nov; 32(11):461-5. PubMed ID: 12499418
[TBL] [Abstract][Full Text] [Related]
12. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
13. T1 GIII bladder cancer. Management with transurethral resection only.
Zungri E; Martinez L; Da Silva EA; Pesqueira D; de la Fuente Buceta A; Pereiro B
Eur Urol; 1999 Nov; 36(5):380-4; discussion 384-5. PubMed ID: 10516446
[TBL] [Abstract][Full Text] [Related]
14. The optimum timing of radical cystectomy for patients with recurrent high-risk superficial bladder tumour.
Solsona E; Iborra I; Rubio J; Casanova J; Almenar S
BJU Int; 2004 Dec; 94(9):1258-62. PubMed ID: 15610101
[TBL] [Abstract][Full Text] [Related]
15. The value of a second transurethral resection for T1 bladder cancer.
Schwaibold HE; Sivalingam S; May F; Hartung R
BJU Int; 2006 Jun; 97(6):1199-201. PubMed ID: 16566814
[TBL] [Abstract][Full Text] [Related]
16. [Conservative treatment with chemotherapy and radiotherapy in bladder cancer invading the muscle: preliminary results of a prospective study].
Zapatero A; Pinar B; Arellano R; López M; Marín A; Jiménez U; Pérez Torrubia A
Arch Esp Urol; 1997 Jun; 50(5):448-54; discussion 454-6. PubMed ID: 9382586
[TBL] [Abstract][Full Text] [Related]
17. Radical transurethral resection and chemotherapy in the treatment of muscle-invasive bladder cancer: a long-term follow-up.
Thomas DJ; Roberts JT; Hall RR; Reading J
BJU Int; 1999 Mar; 83(4):432-7. PubMed ID: 10210567
[TBL] [Abstract][Full Text] [Related]
18. Radical radiotherapy and salvage cystectomy as the primary management of transitional cell carcinoma of the bladder. Results following the introduction of a CT planning technique.
Borgaonkar S; Jain A; Bollina P; McLaren DB; Tulloch D; Kerr GR; Howard GC
Clin Oncol (R Coll Radiol); 2002 Apr; 14(2):141-7. PubMed ID: 12069124
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and Clinical Roles of Different Substaging Systems at First and Second Transurethral Resection in Patients with T1 High-Grade Bladder Cancer.
Colombo R; Hurle R; Moschini M; Freschi M; Colombo P; Colecchia M; Ferrari L; Lucianò R; Conti G; Magnani T; Capogrosso P; Conti A; Pasini L; Burgio G; Guazzoni G; Patriarca C
Eur Urol Focus; 2018 Jan; 4(1):87-93. PubMed ID: 28753746
[TBL] [Abstract][Full Text] [Related]
20. Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder.
Serretta V; Piazza S; Pavone C; Piazza B; Pavone-Macaluso M
Urology; 1996 May; 47(5):647-51. PubMed ID: 8650860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
